NASDAQ:AKRX - Akorn Stock Price, Forecast & News

Akorn trades on the NASDAQ under the ticker symbol "AKRX."

Akorn, Inc. (NASDAQ:AKRX) issued its earnings results on Thursday, October, 31st. The company reported $0.02 EPS for the quarter, beating the Zacks' consensus estimate of ($0.04) by $0.06. The company earned $176.24 million during the quarter, compared to the consensus estimate of $176.15 million. Akorn had a negative return on equity of 19.95% and a negative net margin of 53.62%. Akorn's quarterly revenue was up 6.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.06) earnings per share. View Akorn's Earnings History.

3 brokers have issued 1 year price objectives for Akorn's shares. Their forecasts range from $4.00 to $8.00. On average, they expect Akorn's stock price to reach $5.67 in the next year. This suggests a possible upside of 51.5% from the stock's current price. View Analyst Price Targets for Akorn.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Akorn.

News coverage about AKRX stock has been trending neutral on Tuesday, according to InfoTrie. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Akorn earned a coverage optimism score of 0.4 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Akorn.

Akorn saw a drop in short interest in the month of October. As of October 31st, there was short interest totalling 7,650,000 shares, a drop of 17.6% from the September 30th total of 9,280,000 shares. Based on an average daily volume of 1,860,000 shares, the short-interest ratio is currently 4.1 days. Approximately 8.1% of the company's stock are short sold. View Akorn's Current Options Chain.

Some companies that are related to Akorn include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR) and Zogenix (ZGNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Akorn investors own include Celgene (CELG), Integrated Device Technology (IDTI), Skechers USA (SKX), Rite Aid (RAD), Lannett (LCI), Bank of America (BAC), Quantenna Communications (QTNA), Ulta Beauty (ULTA), Paycom Software (PAYC) and Square (SQ).

Akorn's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (2.66%), State Street Corp (2.60%), Canyon Capital Advisors LLC (2.38%), Mackay Shields LLC (0.57%), Gabelli Funds LLC (0.35%) and Gamco Investors INC. ET AL (0.29%). Company insiders that own Akorn stock include Alan D Weinstein, John N Kapoor, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Institutional Ownership Trends for Akorn.

AKRX stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, State Street Corp, Assenagon Asset Management S.A., Barclays PLC, SG Americas Securities LLC, Chicago Equity Partners LLC and Gabelli Funds LLC. View Insider Buying and Selling for Akorn.

AKRX stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Mackay Shields LLC, Canyon Capital Advisors LLC, Tibra Equities Europe Ltd, State of Alaska Department of Revenue, Nisa Investment Advisors LLC, Gamco Investors INC. ET AL and California Public Employees Retirement System. Company insiders that have bought Akorn stock in the last two years include Alan D Weinstein, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Insider Buying and Selling for Akorn.

Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AKRX stock can currently be purchased for approximately $3.74.

Akorn has a market capitalization of $471.79 million and generates $694.02 million in revenue each year. The company earns $-401,910,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Akorn employs 2,191 workers across the globe.View Additional Information About Akorn.

The official website for Akorn is http://www.akorn.com/.

Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]